Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid-resistant APL cells

Blood

Volumn 100, Issue 7, 2002, Pages 2586-2596

  Côté, Sylvie ^a,b,c   Rosenauer, Angelika ^a,b,c   Bianchini, Andrea ^a,b,c   Seiter, Karen ^a,b,c   Vandewiele, Jonathan ^a,b,c   Nervi, Clara ^a,b,c   Miller Jr , Wilson H ^a,b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; CYTARABINE; ETOPOSIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CELL DIFFERENTIATION; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA HELIX; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; FUSION GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MISSENSE MUTATION; MOLECULAR MODEL; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION REGULATION;

EID: 0036785378     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0614     Document Type: Article

References (83)

1. Miller WH Jr, Warrell RP Jr, Frankel SR, et al. Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to alltrans-retinoic acid. J Natl Cancer Inst. 1990;82:1932-1933.
2. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558-561.
3. Pandolfi PP, Grignani F, Alcalay M, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene. 1991;6:1285-1292.
4. de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675-684.
5. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663-674.
6. He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc Natl Acad Sci U S A. 1997;94:5302-5307.
7. Brown D, Kogan S, Lagasse E, et al. A PML-RARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997;94:2551-2556.
8. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 2001;20:5726-5735.
9. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423-431.
10. Altabef M, Garcia M, Lavau C, et al. A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARα fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J. 1996;15:2707-2716.
11. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
12. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J, 1996;10:940-954.
13. Collingwood TN, Urnov FD, Wolffe AP. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol. 1999;23:255-275.
14. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352.
15. Urnov FD, Wolffe AP, Guschin D. Molecular mechanisms of corepressor function. Curr Top Microbiol Immunol. 2001;254:1-33.
16. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 1997;389:194-198.
17. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997;90:569-580.
18. Nervi C, Poindexter EC, Grignani F, et al. Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. Cancer Res. 1992;52:3687-3692.
19. Perez A, Kastner P, Sethi S, et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 1993;12:3171-3182.
20. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811-814.
21. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391:815-818.
22. He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135.
23. Raelson JV, Nervi C, Rosenauer A, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 1996;88:2826-2832.
24. Castaigne S, Chomienne C, Daniel MT, et al. Alltrans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: clinical results. Blood. 1990;76:1704-1709.
25. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
26. Warrell RP Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood. 1993;82:1949-1953.
27. Cornic M, Chomienne C. Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. Leuk Lymphoma. 1995;18:249-257.
28. Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood. 1993;82:2175-2181.
29. Muindi J, Frankel SR, Miller WH Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992;79:299-303.
30. Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood. 1996;87:725-733.
31. Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 1998;92:1172-1183.
32. Lanotte M, Martin-Thouvenin V, Najman S, et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
33. Duprez E, Ruchaud S, Houge G, et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia. 1992;6:1281-1287.
34. Dermime S, Grignani F, Clerici M, et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. Blood. 1993;82:1573-1577.
35. Rosenauer A, Raelson JV, Nervi C, et al. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood. 1996;88:2671-2682.
36. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood. 1997;89:4282-4289.
37. Kitamura K, Kiyoi H, Yoshida H, et al. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia. Leukemia. 1997;11:1950-1956.
38. Nason-Burchenal K, Allopenna J, Begue A, et al. Targeting of PML/RARα is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood. 1998;92:1758-1767.
39. Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia. 2000;14:255-261.
40. Kizaki M, Matsushita H, Takayama N, et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood. 1996;88:1824-1833.
41. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol. 2001;29:864-872.
42. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 1998;92:374-382.
43. Marasca R, Zucchini P, Galimberti S, et al. Missense mutations in the PML/RARα ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica. 1999;84:963-968.
44. Marasca R, Zucchini P, Iannitelli P, Diverio D, Torelli G, Lo Coco F. PML/RAR alpha mutations in relapsed acute promyelocytic leukemia [abstract]. Joint International Congress on APL and Differentiation Therapy. 2001:34.
45. Zhou DC, Kim SH, Ding W, et al. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99:1356-1363.
46. Côté S, Zhou D, Bianchini A, et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood. 2000;96:3200-3208.
47. Pandolfi PP. Transcription therapy for cancer. Oncogene. 2001;20:3116-3127.
48. Ferrara FF, Fazl F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001;61:2-7.
49. He LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 2001;108:1321-1330.
50. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfl PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621-1625.
51. Roussel MJ, Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene. 2001;20:7287-7291.
52. Momparler RL, Dore BT, Momparler LF. Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett. 1990;54:21-28.
53. Shao W, Rosenauer A, Mann K, et al. Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. Blood. 2000;96:2233-2239.
54. Mader S, Leroy P, Chen JY, Chambon P. Multiple parameters control the selectivity of nuclear receptors for their response elements: selectivity and promiscuity in response element recognition by retinoic acid receptors and retinoid X receptors. J Biol Chem. 1993;268:591-600.
55. Rosenauer A, Nervi C, Davison K, et al. Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression. Cancer Res. 1998;58:5110-5116.
56. Giguère V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature. 1987;330:624-629.
57. Benoit G, Roussel M, Pendino F, Segal-Bendirdjian E, Lanotte M. Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene. 2001;20:7161-7177.
58. Rachez C, Suldan Z, Ward J, et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev. 1998;12:1787-1800.
59. Fondell JD, Ge H, Roeder RG. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci U S A. 1996;93:8329-8333.
60. Nagaya T, Eberhardt NL, Jameson JL. Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutations. J Clin Endocrinol Metab. 1993;77:982-990.
61. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD. Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance: evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest. 1991;88:2123-2130.
62. Collingwood TN, Wagner R, Matthews CH, et al. A role for helix 3 of the TR beta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. EMBO J. 1998;17:4760-4770.
63. Renaud JP, Rochel N, Ruff M, et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 1995;378:681-689.
64. Wurtz JM, Bourguet W, Renaud JP, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol. 1996;3:87-94.
65. Liu Y, Takeshita A, Misiti S, Chin WW, Yen PM. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. Endocrinology. 1998;139:4197-4204.
66. Blondel A, Renaud JP, Fischer S, Moras D, Karplus M. Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. J Mol Biol. 1999;291:101-115.
67. Tagami T, Gu WX, Peairs PT, West BL, Jameson JL. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol. 1998;12:1888-1902.
68. Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene. 2001;20:3047-3054.
69. Nagy L, Kao HY, Love JD, et al. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 1999;13:3209-3216.
70. Perissi V, Staszewski LM, McInerney EM, et al. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 1999;13:3198-3208.
71. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387:733-736.
72. McInerney EM, Rose DW, Flynn SE, et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 1998;12:3357-3368.
73. Bourguet W, Vivat V, Wurtz JM, et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell. 2000;5:289-298.
74. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927-937.
75. Novich SCL, Gallagher RE, Chanel S, et al. Initial clinical evaluation of "transcription therapy" for cancer: all-trans retinoic acid plus phenylbutyrate [abstract]. Blood. 1999;94(suppl 1):61a.
76. Dhordain P, Lin RJ, Quief S, et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998;26:4645-4651.
77. Izutsu K, Kurokawa M, Imai Y, et al. The co-repressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood. 2001;97:2815-2822.
78. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999;59:2766-2769.
79. Kitamura K, Hoshi S, Koike M, et al. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol. 2000;108:696-702.
80. Niitsu N, Hayashi Y, Honma Y. Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23; p13). Oncogene. 2001;20:375-384.
81. Piekarz RL, Robey R, Sandor V. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865-2868.
82. Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 2001;20:1860-1872.
83. Coffey DC, Kutko MC, Glick RD, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 2001;61:3591-3594.